MedCity News September 12, 2024
Sanofi is licensing a RadioMedix radiopharmaceutical in development for neuroendocrine tumors. The French pharmaceutical giant is responsible for global commercialization of the therapy, a potential competitor to the Novartis radiopharmaceutical Lutathera.
Sanofi is following several of its big pharma industry peers into radiopharmaceuticals, striking a deal for a clinical-stage therapy now in discussion for a regulatory submission as a treatment for a rare type of gastrointestinal cancer.
According to deal terms announced Thursday, Sanofi is paying €100 million (about $110 million) to license AlphaMedix, a radiopharmaceutical developed by partners RadioMedix and Orano Med. The upfront payment goes to both companies. If the therapy achieves milestones, Sanofi is responsible for paying them up to €220 million (about $242 million) more, plus...
Today's Sponsors
Today's Sponsor